Help Advance Research for Cognitive Impairment

Evaluating an investigational medication for adults with schizophrenia who experience symptoms like trouble with memory, focus, and staying organized that can make everyday tasks harder.

See If You Qualify

Location

Austin, Texas

Study Type

Inpatient Study

Duration

32-Day Stay

Population

Ages 18–55

About the Study

Advancing mental health discovery.

Community Clinical Research is conducting a randomized study to evaluate the efficacy and safety of an investigational medication, KYN-5356.

The research focuses on helping adults with schizophrenia manage cognitive impairment symptoms that can make everyday tasks like working, studying, or talking with others harder.

What to Expect

A structured 32-day research stay

Inpatient Care

32-day continuous stay at the Austin research clinic.

Medical Testing

Cognitive testing, heart monitoring (ECG), and bloodwork.

Who Can Participate?

Adults aged 18 to 55
Schizophrenia diagnosis (≥1 year)
Clinically stable on medication
Willing to complete the 32-day stay

Benefits & Compensation

Up to $6,600 for completion.

Participants who qualify and complete the study may receive compensation up to $6,600 for their time and travel. All study-related procedures are provided at no cost.

See if you qualify for
this Austin-based study

Help us evaluate new options for cognitive symptoms in schizophrenia.

See If You Qualify

Frequently Asked Questions

The study evaluates the safety and effectiveness of KYN-5356 as an adjunctive treatment for cognitive impairment associated with schizophrenia.

Yes, this specific protocol requires a 32-day continuous inpatient stay at our research facility in Austin, Texas.

Yes, your information is protected and handled in strict accordance with HIPAA and medical privacy regulations.